Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.
Latest Information Update: 03 Nov 2025
At a glance
- Drugs ALY 688 (Primary)
- Indications Dry eyes; Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Allysta Pharmaceuticals
Most Recent Events
- 03 Nov 2025 New trial record